1,5-Diaminoanthraquinone is a key intermediate in the synthesis of various dyes, pigments, and organic colorants. It is typically produced by the reduction of 1,5-dinitroanthraquinone. Research focuses on developing sustainable and environmentally friendly methods for its synthesis. 1,5-Diaminoanthraquinone exhibits antioxidant properties and has been studied for its potential applications in medical fields. Its importance stems from its versatile nature as a building block for various organic compounds with diverse applications.'
1,5-diaminoanthraquinone: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 8513 |
| CHEMBL ID | 90387 |
| SCHEMBL ID | 64318 |
| MeSH ID | M0516540 |
| Synonym |
|---|
| BIDD:GT0325 |
| 1,5-diamino-anthraquinone |
| CHEMBL90387 |
| 1,5-daa [russian] |
| 9,10-anthracenedione, 1,5-diamino- |
| 1,5-diaminoanthrachinon [czech] |
| einecs 204-947-2 |
| nsc 7213 |
| ccris 5609 |
| anthraquinone, 1,5-diamino- |
| smoke red f |
| 1,5-diamino-9,10-anthraquinone |
| brn 2215892 |
| nsc 63791 |
| UPCMLD0ENAT5883787:001 |
| 1,5-diaminoanthrachinon |
| anthraquinone,5-diamino- |
| wln: l c666 bv ivj dz kz |
| 129-44-2 |
| 1,5-anthraquinonyldiamine |
| 1,5-daa |
| c.i. disperse red ii |
| 1,5-diaminoanthraquinone |
| nsc-7213 |
| 9, 1,5-diamino- |
| nsc7213 |
| NCI60_041509 |
| nsc63791 |
| nsc-63791 |
| anthraquinone, 1,5-diamino |
| PRESTWICK_161 |
| inchi=1/c14h10n2o2/c15-9-5-1-3-7-11(9)14(18)8-4-2-6-10(16)12(8)13(7)17/h1-6h,15-16h |
| 1,5-diaminoanthraquinone, technical grade, 85% |
| NCIOPEN2_002796 |
| STK874274 |
| 1,5-diaminoanthracene-9,10-dione |
| D1268 |
| AKOS000119638 |
| A805940 |
| unii-3zxx3hk358 |
| 3zxx3hk358 , |
| FT-0606948 |
| nsc-507213 |
| SCHEMBL64318 |
| 1,5-diamino-9,10-dihydroanthracene-9,10-dione |
| DTXSID1059602 |
| 1,5-diaminoanthra-9,10-quinone # |
| W-108362 |
| mfcd00001226 |
| 1,5-diaminoanthraquinone, 97% |
| Z57379624 |
| EN300-18214 |
| Q27258270 |
| D89823 |
| 111641-58-8 |
| SY048855 |
| CS-0010166 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 330.5000 | 0.0007 | 1.6003 | 10.0000 | AID144609; AID144610 |
| Glutamate receptor ionotropic, NMDA 2A | Rattus norvegicus (Norway rat) | IC50 (µMol) | 330.5000 | 0.0007 | 1.6306 | 10.0000 | AID144609; AID144610 |
| Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | IC50 (µMol) | 330.5000 | 0.0006 | 1.5257 | 10.0000 | AID144609; AID144610 |
| Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | IC50 (µMol) | 330.5000 | 0.0007 | 1.7472 | 10.0000 | AID144609; AID144610 |
| Glutamate receptor ionotropic, NMDA 2D | Rattus norvegicus (Norway rat) | IC50 (µMol) | 330.5000 | 0.0007 | 1.7411 | 10.0000 | AID144609; AID144610 |
| Glutamate receptor ionotropic, NMDA 3B | Rattus norvegicus (Norway rat) | IC50 (µMol) | 330.5000 | 0.0007 | 1.7411 | 10.0000 | AID144609; AID144610 |
| Glutamate receptor ionotropic, NMDA 3A | Rattus norvegicus (Norway rat) | IC50 (µMol) | 330.5000 | 0.0007 | 1.7411 | 10.0000 | AID144609; AID144610 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID144609 | Displacement of [3H]MK-801 from N-methyl-D-aspartate glutamate receptor | 2000 | Bioorganic & medicinal chemistry letters, Dec-04, Volume: 10, Issue:23 | Aminoanthraquinones as novel ligands at the polyamine binding site on the N-methyl-D-aspartate receptor complex. |
| AID144610 | Displacement of [3H]-SPD from N-methyl-D-aspartate glutamate receptor | 2000 | Bioorganic & medicinal chemistry letters, Dec-04, Volume: 10, Issue:23 | Aminoanthraquinones as novel ligands at the polyamine binding site on the N-methyl-D-aspartate receptor complex. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (24.68) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||